| NodThera Adds $55M to Advance Drugs to Better Regulate Inflammation | Sarah de Crescenzo | 06/03/20 | Boston |
| Pliant Therapeutics Prices IPO, Lands $144M to Test Fibrosis Drugs | Frank Vinluan | 06/03/20 | San Francisco |
| Pliant Pushes Forward With IPO Plans to Back Fibrosis Drug Studies | Frank Vinluan | 05/12/20 | San Francisco |
| Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More | Sarah de Crescenzo | 05/01/20 | National |
| miRagen Restructures to Focus on Fibrosis, Inks $20M Stock Deal | Frank Vinluan | 12/12/19 | Boulder/Denver |
| Gilead Ups Stake in Galapagos With $5B Deal to Jumpstart Its R&D | Ben Fidler | 07/15/19 | San Francisco |
| West Coast Bio Roundup: CRISPR Patent, HCV Data, Verily Digs & More | Alex Lash | 02/19/16 | San Francisco |
| Bristol-Myers Makes $150M Bet on Promedior, Fibrosis Drug | Ben Fidler | 08/31/15 | Boston |
| Tiger Teams, Dropping Subs, and Biotech’s Elusive Second Strikes | Alex Lash | 03/03/15 | National |
| As Rival Sputters, FibroGen Heads to Nasdaq Via $146M IPO | Ben Fidler | 11/14/14 | San Francisco |
| East Coast Biotech Roundup: Intercept, Idera, Inotek, & More | Ben Fidler | 11/07/14 | Boston |
| West Coast Biotech Roundup: Amgen, Inslee, Fibrogen, Receptos & More | Alex Lash | 10/30/14 | Seattle |
| West Coast Biotech Roundup: Illumina, Atara, Invitae, Canaan & More | Alex Lash | 10/17/14 | San Francisco |
| West Coast Biotech Roundup: ARCH, Ebola, ViaCyte, Calithera & More | Alex Lash | 08/28/14 | San Francisco |
| Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis? | Alex Lash | 08/25/14 | San Francisco |
| Gilead Sciences Building on HIV, Becoming Cancer Drug Force | Luke Timmerman | 04/01/13 | National |
| San Diego Life Sciences Roundup: Deals at MEI Pharma, Auspex, Ambit | Bruce V. Bigelow | 11/09/12 | San Diego |
| Promedior Moves Fibrosis Pipeline to Boston, Hires Shire Vet as CEO | Arlene Weintraub | 05/15/12 | Boston |
| Genoa Pharma Aims To Satisfy Big Pharma’s Hunger for IPF Drugs | Luke Timmerman | 03/30/12 | San Diego |
| Biogen Idec Lets Stromedix Do The Hard Part | Steve Dickman | 02/14/12 | Boston |
| Biogen Buys Stromedix for $75M, Regaining Fibrosis Drug | Arlene Weintraub | 02/14/12 | Boston |
| Amira Pharma on How it Beat the Odds, and Sold an Early Stage Drug to Bristol-Myers for $325M | Luke Timmerman | 09/07/11 | San Diego |
| UCSF Nabs $48M Gift | Luke Timmerman | 02/28/11 | San Francisco |
| Stromedix Chief, After Reloading the Company Treasury, Sets Sight on Trial for Deadly Lung Disease | Ryan McBride | 02/07/11 | Boston |
| Gilead Buys Arresto for $225M | Luke Timmerman | 12/20/10 | San Francisco |
| Amira Cuts Half of Staff, Scientific Founders Exit as Company Seeks to Conserve Cash | Luke Timmerman | 11/23/10 | San Diego |
| Stromedix, with Biogen Idec Roots, Seeks Exit from Regulatory Limbo | Ryan McBride | 07/20/10 | Boston |
| Amira Mixes Small Biotech Irreverence, With Big Pharma Rigor, To Create New Lung Drugs | Luke Timmerman | 01/28/10 | San Diego |
| Gilead Deepens Roots in Seattle, Seeks Long-Term Payoff From Lung Disease Research | Luke Timmerman | 01/13/10 | Seattle |
